References
- Beumer JH, Beijnen JH, Schellens JH. (2006). Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33–58.
- Bigaud M, Guerini D, Billich A, et al. (2014). Second generation S1P pathway modulators: research strategies and clinical developments. Biochim Biophys Acta 1841:745–58.
- Graham RA, Lum BL, Morrison G, et al. (2011). A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 39:1460–7.
- Harada T, Wilbraham D, de La Borderie G, et al. (2017). Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects. Br J Clin Pharmacol 83:1011–27.
- Hop CE, Wang Z, Chen Q, Kwei G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3.
- Kappos L, Arnold DL, Bar-Or A, et al. (2016). Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 15:1148–59.
- Mazurais D, Robert P, Gout B, et al. (2002). Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50:661–70.
- Prakash C, Johnson KA, Gardner MJ. (2008). Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab Dispos 36:1218–26.
- Sugahara K, Maeda Y, Shimano K, et al. (2017). Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol 174:15–27.
- Vaclavkova A, Chimenti S, Arenberger P, et al. (2014). Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 384:2036–45.
- Zollinger M, Gschwind HP, Jin Y, et al. (2011). Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos 39:199–207.